Conmed Stock Analysis
CNMD Stock | USD 70.62 0.61 0.86% |
CONMED is undervalued with Real Value of 86.61 and Target Price of 135.14. The main objective of CONMED stock analysis is to determine its intrinsic value, which is an estimate of what CONMED is worth, separate from its market price. There are two main types of CONMED's stock analysis: fundamental analysis and technical analysis.
The CONMED stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and CONMED's ongoing operational relationships across important fundamental and technical indicators.
CONMED |
CONMED Stock Analysis Notes
About 99.0% of the company shares are held by institutions such as insurance companies. The book value of CONMED was currently reported as 30.21. The company has Price/Earnings (P/E) ratio of 188.03. CONMED last dividend was issued on the 20th of December 2024. The entity had 3:2 split on the 10th of September 2001. CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida. C O operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 3800 people. For more info on CONMED please contact Curt Hartman at 727 392 6464 or go to https://www.conmed.com.CONMED Quarterly Total Revenue |
|
CONMED Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. CONMED's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding CONMED or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Over 99.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: Are You a Growth Investor This 1 Stock Could Be the Perfect Pick |
CONMED Upcoming and Recent Events
31st of January 2024 Upcoming Quarterly Report | View | |
24th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
31st of January 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
CONMED Largest EPS Surprises
Earnings surprises can significantly impact CONMED's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2009-07-30 | 2009-06-30 | 0.15 | 0.17 | 0.02 | 13 | ||
1997-04-17 | 1997-03-31 | 0.19 | 0.17 | -0.02 | 10 | ||
2006-10-26 | 2006-09-30 | 0.19 | 0.22 | 0.03 | 15 |
CONMED Environmental, Social, and Governance (ESG) Scores
CONMED's ESG score is a quantitative measure that evaluates CONMED's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of CONMED's operations that may have significant financial implications and affect CONMED's stock price as well as guide investors towards more socially responsible investments.
CONMED Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Geode Capital Management, Llc | 2024-09-30 | 693.4 K | Cooke & Bieler Lp | 2024-09-30 | 668.8 K | Principal Financial Group Inc | 2024-09-30 | 620.7 K | Deerfield Management Co | 2024-09-30 | 614.9 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 501.8 K | Clearbridge Advisors, Llc | 2024-09-30 | 496.4 K | Jpmorgan Chase & Co | 2024-09-30 | 424.7 K | Wells Fargo & Co | 2024-09-30 | 413.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 381.4 K | Blackrock Inc | 2024-06-30 | 5 M | Vanguard Group Inc | 2024-09-30 | 3.5 M |
CONMED Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.18 B.CONMED Profitablity
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.08 | 0.07 | |
Return On Capital Employed | 0.07 | 0.09 | |
Return On Assets | 0.03 | 0.04 | |
Return On Equity | 0.08 | 0.07 |
Management Efficiency
CONMED has return on total asset (ROA) of 0.0398 % which means that it generated a profit of $0.0398 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1524 %, meaning that it created $0.1524 on every $100 dollars invested by stockholders. CONMED's management efficiency ratios could be used to measure how well CONMED manages its routine affairs as well as how well it operates its assets and liabilities. At present, CONMED's Return On Assets are projected to slightly decrease based on the last few years of reporting. At present, CONMED's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 100.9 M, whereas Net Tangible Assets are projected to grow to (642.7 M).Last Reported | Projected for Next Year | ||
Book Value Per Share | 27.20 | 28.56 | |
Tangible Book Value Per Share | (20.29) | (19.27) | |
Enterprise Value Over EBITDA | 22.47 | 19.14 | |
Price Book Value Ratio | 4.03 | 4.23 | |
Enterprise Value Multiple | 22.47 | 19.14 | |
Price Fair Value | 4.03 | 4.23 | |
Enterprise Value | 780.6 M | 819.6 M |
CONMED has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Dividend Yield 0.0113 | Operating Margin 0.1222 | Profit Margin 0.1023 | Forward Dividend Yield 0.0113 | Beta 1.461 |
Technical Drivers
As of the 29th of December, CONMED shows the mean deviation of 1.78, and Risk Adjusted Performance of (0). CONMED technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CONMED variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if CONMED is priced favorably, providing market reflects its regular price of 70.62 per share. Given that CONMED has information ratio of (0.03), we suggest you to validate CONMED's prevailing market performance to make sure the company can sustain itself in the future.CONMED Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. CONMED middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for CONMED. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
CONMED Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CONMED insiders, such as employees or executives, is commonly permitted as long as it does not rely on CONMED's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CONMED insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CONMED Outstanding Bonds
CONMED issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CONMED uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CONMED bonds can be classified according to their maturity, which is the date when CONMED has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
CONMED Predictive Daily Indicators
CONMED intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CONMED stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CONMED Corporate Filings
8K | 10th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 6th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
CONMED Forecast Models
CONMED's time-series forecasting models are one of many CONMED's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CONMED's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About CONMED Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how CONMED prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CONMED shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as CONMED. By using and applying CONMED Stock analysis, traders can create a robust methodology for identifying CONMED entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.06 | 0.08 | |
Operating Profit Margin | 0.11 | 0.11 | |
Net Profit Margin | 0.05 | 0.05 | |
Gross Profit Margin | 0.54 | 0.42 |
Current CONMED Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CONMED analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CONMED analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
135.14 | Buy | 7 | Odds |
Most CONMED analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CONMED stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of CONMED, talking to its executives and customers, or listening to CONMED conference calls.
CONMED Stock Analysis Indicators
CONMED stock analysis indicators help investors evaluate how CONMED stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading CONMED shares will generate the highest return on investment. By understating and applying CONMED stock analysis, traders can identify CONMED position entry and exit signals to maximize returns.
Begin Period Cash Flow | 28.9 M | |
Long Term Debt | 973.1 M | |
Common Stock Shares Outstanding | 31.5 M | |
Total Stockholder Equity | 834.2 M | |
Tax Provision | -28.4 M | |
Quarterly Earnings Growth Y O Y | 2.14 | |
Property Plant And Equipment Net | 120.7 M | |
Cash And Short Term Investments | 24.3 M | |
Cash | 24.3 M | |
Accounts Payable | 88.2 M | |
Net Debt | 967 M | |
50 Day M A | 70.8388 | |
Total Current Liabilities | 310.7 M | |
Other Operating Expenses | 1.1 B | |
Non Current Assets Total | 1.7 B | |
Forward Price Earnings | 27.027 | |
Non Currrent Assets Other | 96.1 M | |
Stock Based Compensation | 24.3 M |
Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |